Abstract:
Objective To explore the efficacy and safety of weekly liposome-paclitaxel versus oxaliplatin with tegafur (S-1) as the first-line therapy on elderly advanced gastric cancer patients.
Methods A total of 119 elderly patients with advanced gastric cancer were randomly divided into Group A (62 cases) and Group B (57 cases). In Group A, liposome-paclitaxel combined with S-1 was administered; in Group B, oxaliplatin combined with S-1 was applied. The short-term efficacy, median progression free survival(PFS), median overall survival(OS), Karnofsky performance status score and adverse reactions of the two groups were observed and compared.
Results No significant difference was observed in the objective response rate (ORR), disease control rate(DCR), median PFS and median OS between Group A and Group B (22.0% vs. 25.0%, 69.5% vs. 67.9%, 6.4 vs. 6.4 months, 10.8 vs. 10.4 months; all P>0.05). The incidence of degrees Ⅰ-Ⅱ nausea and vomiting and peripheral nerve toxicity were significantly higher in Group B than those in Group A (all P< 0.05).
Conclusion The short-term efficacy of weekly liposome-paclitaxel combined with S-1 treatment was same with oxaliplatin combined with S-1 treatment, and the former treatment has a tendency of lower toxicity and could be recommended as the optimal treatment for the elderly advanced gastric cancer patients.